VTRS
Viatris Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$18.48
+0.16%Price chart
Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22
Key dataOct 22, 2026
Open$18.45
From 52W high−0.94%
Volume5.44M
Market cap$21.23B
P/E (TTM)—
P/S (TTM)1.4x
Div yield1.95%
Key dataOct 22, 2026
Open
$18.45
From 52W high
−0.94%
Volume
5.44M
Market cap
$21.23B
ValuationView details →
P/E (Fwd)
7.0x
EV/EBITDA
12.3x
P/E (TTM)
—
RSI (14)
61.7
MomentumView details →
1D Return
+0.16%
YTD Return
+48.15%
SummaryUpdated Jun 1, 2026
Viatris Inc. (NASDAQ:VTRS) is a global healthcare company formed in 2020 through the merger of Mylan N.V. and Pfizer's Upjohn division. The company traces its roots back to 1961 and represents one of the world's largest generic and specialty pharmaceutical companies. Headquartered in Canonsburg, Pennsylvania, Viatris operates across more than 165 countries and serves over one billion patients annually with a diverse portfolio of prescription medicines, biosimilars, and active pharmaceutical ingredients.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration approved Viatris’ RYZUMVI for treating presbyopia in adults.6d agoBrodsky & Smith announced an investigation into potential claims against Pacira BioSciences' board concerning its proposed sale to Viatris.14d agoViatris Inc agreed to acquire all outstanding shares of Pacira BioSciences, Inc. for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.15d ago